[go: up one dir, main page]

CA2423628A1 - Derives de tryptamines et composes analogues, et formulation pharmaceutique contenant de tels derives - Google Patents

Derives de tryptamines et composes analogues, et formulation pharmaceutique contenant de tels derives Download PDF

Info

Publication number
CA2423628A1
CA2423628A1 CA002423628A CA2423628A CA2423628A1 CA 2423628 A1 CA2423628 A1 CA 2423628A1 CA 002423628 A CA002423628 A CA 002423628A CA 2423628 A CA2423628 A CA 2423628A CA 2423628 A1 CA2423628 A1 CA 2423628A1
Authority
CA
Canada
Prior art keywords
compound according
alkyl
dinitro
aryl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002423628A
Other languages
English (en)
Other versions
CA2423628C (fr
Inventor
Nava Zisapel
Moshe Laudon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2423628A1 publication Critical patent/CA2423628A1/fr
Application granted granted Critical
Publication of CA2423628C publication Critical patent/CA2423628C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à de nouvelles tryptamines substituées et à des dérivés associés, ainsi qu'à des compositions pharmaceutiques préparées à partir de ces tryptamines. Ces composés, compositions et leurs sels peuvent être utilisés pour la fabrication de médicaments permettant une interaction avec le système mélatoninergique. Ces composés et compositions peuvent être utilisés pour le traitement de divers types d'états pathologiques, tels que des troubles psychiatriques et des troubles du système nerveux central (troubles du sommeil, épilepsie et autres troubles convulsifs, anxiété, maladies neurodégénératives), troubles des rythmes chronobiologiques (décalage horaire, syndrome du sommeil retardé, travail par postes, trouble affectif saisonnier), troubles néoplasiques et états pathologiques associés à la sénescence.
CA2423628A 2000-10-03 2001-09-25 Derives de tryptamines et composes analogues, et formulation pharmaceutique contenant de tels derives Expired - Fee Related CA2423628C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL138825 2000-10-03
IL138825A IL138825A (en) 2000-10-03 2000-10-03 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
PCT/IL2001/000898 WO2002028347A2 (fr) 2000-10-03 2001-09-25 Derives de tryptamines et composes analogues, et formulation pharmaceutique contenant de tels derives

Publications (2)

Publication Number Publication Date
CA2423628A1 true CA2423628A1 (fr) 2002-04-11
CA2423628C CA2423628C (fr) 2011-04-26

Family

ID=11074694

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2423628A Expired - Fee Related CA2423628C (fr) 2000-10-03 2001-09-25 Derives de tryptamines et composes analogues, et formulation pharmaceutique contenant de tels derives

Country Status (39)

Country Link
US (2) US6780884B2 (fr)
EP (1) EP1331935B1 (fr)
JP (1) JP2004533986A (fr)
KR (1) KR100855385B1 (fr)
CN (1) CN100518735C (fr)
AR (1) AR035587A1 (fr)
AT (1) ATE409474T1 (fr)
AU (1) AU9416201A (fr)
BG (1) BG107759A (fr)
BR (1) BR0114464A (fr)
CA (1) CA2423628C (fr)
CL (1) CL2001002303A1 (fr)
CR (1) CR6968A (fr)
CY (1) CY1110417T1 (fr)
CZ (1) CZ301098B6 (fr)
DE (1) DE60136003D1 (fr)
DK (1) DK1331935T3 (fr)
EA (1) EA005918B1 (fr)
EE (1) EE05192B1 (fr)
ES (1) ES2315307T3 (fr)
GT (1) GT200100197A (fr)
HN (1) HN2001000218A (fr)
HU (1) HU227163B1 (fr)
IL (1) IL138825A (fr)
IS (1) IS2607B (fr)
MX (1) MXPA03002612A (fr)
NO (1) NO20031396L (fr)
NZ (1) NZ525587A (fr)
PA (1) PA8529801A1 (fr)
PE (1) PE20020411A1 (fr)
PL (1) PL365679A1 (fr)
PT (1) PT1331935E (fr)
SI (1) SI1331935T1 (fr)
SK (1) SK4042003A3 (fr)
TW (1) TWI270544B (fr)
UA (1) UA75091C2 (fr)
UY (1) UY26946A1 (fr)
WO (1) WO2002028347A2 (fr)
ZA (1) ZA200303113B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515429A (ja) * 2003-12-19 2007-06-14 エリクシアー ファーマシューティカルズ， インコーポレイテッド 障害を治療する方法
EP1715742A4 (fr) * 2004-02-20 2009-06-17 Lifescape Biosciences Inc Compositions et methodes de regulation du sommeil
KR20080031266A (ko) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Ｐａｒｐ 조절제 및 암의 치료
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
CA2729006C (fr) 2007-06-29 2017-01-31 Clarencew Pty Ltd Traitement ou prophylaxie de troubles neurologiques ou neuropsychiatriques par administration oculaire
DK2291659T3 (en) * 2008-05-13 2015-12-21 Univ Yale SMALL CHEMICAL MOLECULES FOR RECRUITING ANTIBODIES TO CANCER CELLS
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
KR102407182B1 (ko) 2011-05-31 2022-06-10 클라렌슈 피티와이 리미티드 광선 요법 장치
US9073851B2 (en) 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
TWI733772B (zh) * 2016-03-14 2021-07-21 美商身體邏輯股份有限公司 用於合成吲哚環核鹼基結合物之組成物及方法
CN116421600B (zh) * 2023-05-29 2024-08-23 重庆医科大学 色醇在制备治疗焦虑的药物中的应用
WO2025137730A1 (fr) * 2023-12-22 2025-06-26 Alexander Shulgin Research Institute, Inc. Tryptamines n-substituées et lysergamides n-substitués et leur utilisation comme agents thérapeutiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6310085B1 (en) * 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders

Also Published As

Publication number Publication date
IS2607B (is) 2010-04-15
IS6752A (is) 2003-03-21
CZ2003940A3 (cs) 2003-10-15
CZ301098B6 (cs) 2009-11-04
IL138825A (en) 2006-06-11
WO2002028347A2 (fr) 2002-04-11
NO20031396D0 (no) 2003-03-27
BG107759A (bg) 2004-01-30
PL365679A1 (en) 2005-01-10
EP1331935A2 (fr) 2003-08-06
ES2315307T3 (es) 2009-04-01
MXPA03002612A (es) 2004-04-02
ZA200303113B (en) 2004-07-23
TWI270544B (en) 2007-01-11
GT200100197A (es) 2002-05-08
KR20030051689A (ko) 2003-06-25
US20040029950A1 (en) 2004-02-12
EA200300436A1 (ru) 2003-10-30
CR6968A (es) 2004-02-25
PT1331935E (pt) 2009-01-19
EP1331935B1 (fr) 2008-10-01
AU9416201A (en) 2002-04-15
CN1582147A (zh) 2005-02-16
CA2423628C (fr) 2011-04-26
HK1074163A1 (zh) 2005-11-04
UY26946A1 (es) 2001-11-30
BR0114464A (pt) 2004-01-20
WO2002028347A3 (fr) 2002-07-04
HN2001000218A (es) 2002-05-09
CN100518735C (zh) 2009-07-29
HU227163B1 (en) 2010-09-28
US20050020664A1 (en) 2005-01-27
ATE409474T1 (de) 2008-10-15
KR100855385B1 (ko) 2008-09-04
UA75091C2 (en) 2006-03-15
EA005918B1 (ru) 2005-06-30
AR035587A1 (es) 2004-06-16
DK1331935T3 (da) 2009-02-02
PE20020411A1 (es) 2002-05-16
CY1110417T1 (el) 2015-04-29
NZ525587A (en) 2005-03-24
NO20031396L (no) 2003-03-27
HUP0302616A2 (hu) 2003-11-28
US6780884B2 (en) 2004-08-24
EE200300135A (et) 2003-08-15
EP1331935A4 (fr) 2004-12-01
EE05192B1 (et) 2009-08-17
CL2001002303A1 (es) 2010-06-25
SK4042003A3 (en) 2003-09-11
PA8529801A1 (es) 2002-12-30
IL138825A0 (en) 2001-10-31
SI1331935T1 (sl) 2009-04-30
JP2004533986A (ja) 2004-11-11
DE60136003D1 (de) 2008-11-13

Similar Documents

Publication Publication Date Title
CA2423628A1 (fr) Derives de tryptamines et composes analogues, et formulation pharmaceutique contenant de tels derives
ATE280170T1 (de) Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indole als 5ht2c antagonisten
CA2642465A1 (fr) Nouveaux derives d'indolopyrone et leur procede de preparation
CA2131797A1 (fr) Derives condenses de l'indole utilises comme antagonistes du recepteur 5ht4
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
GR3021874T3 (en) Improvements in or relating to excitatory amino acid receptor antagonists
JP2009526831A5 (fr)
ATE279192T1 (de) Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung
ES482787A1 (es) Un procedimiento para preparar derivados de flavano, mono- di-y tri-sustituidos.
KR100749991B1 (ko) 인돌 유도체
JP2004533986A5 (fr)
EP0539281B1 (fr) Dérivés de naphtamides, leur procédé de préparation et leur application dans le domaine thérapeutique
NO923413L (no) Terapeutiske benzazepin-forbindelser
CA2388470A1 (fr) Utilisation de derives carbonylamino contre les troubles du systeme nerveux central
CA2523253A1 (fr) Methyle indoles et methyle pyrrolopyridines servant d'agonistes du recepteur adrenergique alpha-1
KR950700257A (ko) 콜레시스토키닌 길항제로서 유용한 3-페닐우레이도-아제핀-2-온 및 벤즈아제핀-2-온(3-phenylureido-azepin-2-ones and-benzazepin-2-ones useful as cholecystokinin antagonists)
AU660969B2 (en) NMDA antagonists
AR016672A1 (es) Ligandos del receptor h3 del tipo fenil-alquil-imidazoles, composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de unmedicamento
WO2022033303A1 (fr) Dérivé de benzylamine, son procédé de préparation et son utilisation
KR950704236A (ko) 신규한 페닐에틸 및 페닐프로필아민(Novel Phenylethyl and Phenylpropylamines)
ES2181387T3 (es) Derivados de azetidinocarboxamida para el tratamiento de trastornos del sistema nervioso central.
RU2347783C2 (ru) Производные диазепана, их применение в качестве ингибиторов lfa, способ лечения заболеваний, опосредованных взаимодействием с lfa-1/icam-1
AU689277B2 (en) Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
RU2186061C2 (ru) 1-изопропил-2-формил-3-аминопиразолидины, обладающие противовоспалительной, анальгезирующей, антипиретической и противогипоксической активностью
ES2154828T3 (es) Uso de derivados de fenoxipiridina para el tratamiento de enfermedades causadas por trastornos del sistema dopamina.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed